Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes.
about
Does accumulation of advanced glycation end products contribute to the aging phenotype?[Protein glycation as a pathological mechanism in diabetes].Advanced glycation end products and oxidative stress in type 2 diabetes mellitus.Inflammatory cytokines as predictive markers for early detection and progression of diabetic nephropathyGlycation products as markers and predictors of the progression of diabetic complications.Prevention of advanced glycation end-products formation in diabetic rats through beta-cell modulation by Aegle marmelosAlbuminuria and rapid loss of GFR and risk of new hip and pelvic fracturesAnalysis of advanced glycation end products in the DHS Mind Study.Anti-Apoptotic and Pro-Survival Effect of Alpinate Oxyphyllae Fructus (AOF) in a d-Galactose-Induced Aging Heart.Carboxymethyl lysine, an advanced glycation end product, and incident diabetes: a case-cohort analysis of the ARIC Study.Potential biomarkers of ageing.Novel insights in the treatment of diabetic nephropathy.Acute carbonyl stress induces occludin glycation and brain microvascular endothelial barrier dysfunction: role for glutathione-dependent metabolism of methylglyoxal.The Antioxidant Potential of Azadirachta indica Ameliorates Cardioprotection Following Diabetic Mellitus-Induced Microangiopathy.Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.The antihypertensive effect of arginine.Advanced glycation end products induce brain-derived neurotrophic factor release from human platelets through the Src-family kinase activation.Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanismsAn update on advanced glycation endproducts and atherosclerosis.Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology.Damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways.Consequences of Advanced Glycation End Products Accumulation in Chronic Kidney Disease and Clinical Usefulness of Their Assessment Using a Non-invasive Technique - Skin Autofluorescence.Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method.Transferrin modifications and lipid peroxidation: implications in diabetes mellitus.Nephropathy, but not retinopathy, is associated with the development of heart disease in Type 1 diabetes: a 12-year observation study of 462 patients.Methylglyoxal mediates vascular inflammation via JNK and p38 in human endothelial cells.Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients.The AGE-RAGE Axis: Implications for Age-Associated Arterial Diseases.Arterial-ventricular coupling in type 1 diabetes: arterial stiffness is associated with impaired global longitudinal strain in type 1 diabetes patients-the Thousand & 1 Study.Advanced glycation end products attenuate the function of tumor necrosis factor-like weak inducer of apoptosis to regulate the inflammatory response.Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults.AGEing heart valves: a bittersweet stiffening process?Circulating Concentrations of Redox Biomarkers Do Not Improve the Prediction of Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus.AGE/RAGE-Induced EMP Release via the NOX-Derived ROS Pathway.Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial
P2860
Q24632710-F6D0582F-897A-49F1-BE66-D60738D35AC3Q30318169-F128E305-C917-45B9-80FB-AE5DE2F233ADQ35255473-D69C0500-1136-4BCA-915D-5EAD3A400C7AQ36117573-F867841A-1855-42D5-9622-4F63225238B3Q36203971-58A5434B-8B2D-4B73-BD08-E1A652E4A5A8Q36353847-B5290EA4-118B-4169-B9DB-E7B3BC1A81BFQ36583378-283B1581-0845-4E1B-9F55-8C55BD11777AQ36600193-A4039DA2-4E6A-4CFA-8E51-6D16AFC6CA70Q36846937-AED3D8E8-42AB-4F0E-9355-B49D0AE43998Q37056383-16AC7B32-1F97-420B-BF9C-0D4C42ED233FQ37061417-B183775C-A8A5-403A-8340-58AD917C8379Q37070946-7496862F-F862-430F-9014-1D88B2313E3CQ37092147-91EBE3F9-0DCA-4099-BC4D-2B4A3F4F3297Q37149021-C17CE5D5-2659-4128-A09C-C55A463B1143Q37267277-7F9C67EB-CC93-4A0F-8228-44C48A884F49Q37309054-3BA57A07-3A5B-4503-A436-4F94F7AEEF9BQ37633629-4C817160-E6D3-478A-9704-D2155CC427CAQ37636453-BD16C3BE-2CEF-4E48-AD95-0013EEA2F609Q38001410-AF2A77CE-94E9-4F2A-ACAA-D7185511E0AFQ38108373-181768B6-B09E-4CF7-A5D9-895C98BB0654Q38620860-0EA77914-B6D3-4772-95CF-DD3FB02CFFC6Q42120056-8DE931D5-1434-4988-9E25-E57DE1D7898CQ44642876-933EDDA7-ACCA-49FA-AD6B-75F82A3972D9Q44712032-57D02E0F-3A12-4C3B-BB80-4C808AE2F487Q45232377-A7831F2A-F054-4F48-897F-04C0A36102EBQ46325452-8FA8AC00-070B-4136-B453-13D36099CB8BQ46495572-E17709A8-F0C7-417C-ABFA-6276C98926D9Q47094524-66245F4D-BB75-49E5-91BA-BA03C8AFFAF6Q48177814-E82747C2-4BCC-4BE3-93A9-139E2AFB62FEQ50690444-A5D1BC36-9915-489C-BF86-2C9E6DA2AF41Q51370614-5F70A163-D713-4392-B583-858990394EDDQ51675302-7B25F195-5754-44EF-AA8F-A1750F8AE274Q52686161-2BBBBF21-37DB-44D1-8B90-C7111C1CB94EQ55361805-0B5D7938-72E6-40AE-88B9-765FFCCA0797Q58729789-7833026D-2B7D-47D1-A512-C2D3C599DB1E
P2860
Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Serum concentrations of advanc ...... patients with type 2 diabetes.
@ast
Serum concentrations of advanc ...... patients with type 2 diabetes.
@en
type
label
Serum concentrations of advanc ...... patients with type 2 diabetes.
@ast
Serum concentrations of advanc ...... patients with type 2 diabetes.
@en
prefLabel
Serum concentrations of advanc ...... patients with type 2 diabetes.
@ast
Serum concentrations of advanc ...... patients with type 2 diabetes.
@en
P2093
P356
P1433
P1476
Serum concentrations of advanc ...... patients with type 2 diabetes.
@en
P2093
P2888
P356
10.1007/S005920070025
P577
2000-01-01T00:00:00Z
P6179
1020683395